Anti-RhoB Antibodies for Retinal Vascularization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular diseases characterized by aberrant vascularization, such as diabetic retinopathy and macular degeneration, are inadequate in effectively inhibiting or treating abnormal blood vessel growth and avascular pathology around the optic nerve.
Innovation Solution
Administration of antibodies or antibody fragments immunologically specific for RhoB, either alone or in combination with other therapeutic agents, to inhibit or treat ocular diseases by targeting and regulating vascularization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for ocular diseases characterized by aberrant vascularization, then treatment is provided, but the treatments are inadequate in effectively inhibiting or treating abnormal blood vessel growth and avascular pathology
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (RhoB protein) that drives aberrant vascularization in ocular diseases. By isolating and neutralizing this specific pathological driver through anti-RhoB antibodies, the treatment achieves high effectiveness against abnormal blood vessel growth without requiring complex multi-target approaches.
Solution Approach 2:
The patent changes the therapeutic parameter from general anti-angiogenic approaches to specifically targeting RhoB protein activity. This parameter change enables precise inhibition of pathological vascularization while preserving normal vascular function, resolving the contradiction between treatment effectiveness and approach complexity.
2Reliability
If anti-RhoB antibodies are administered to normalize vascularization, then abnormal neovascularization and avascular pathology are reduced, but the complexity of the treatment increases
Solution Approach 1:
The patent introduces anti-RhoB antibodies as intermediary molecules that specifically bind to and neutralize the RhoB protein. This intermediary approach allows for precise control of vascularization processes, achieving normalization effects while the antibody itself serves as a ready-to-administer therapeutic agent, minimizing additional complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of anti-RhoB antibodies normalizes vascularization in the retina, reducing abnormal neovascularization and avascular pathology, as demonstrated in models of retinopathy and macular degeneration, thereby providing a therapeutic benefit for these conditions.
Implementation Method 1
administration of at least one antibody or antibody fragment immunologically specific for RhoB
Data Source
AI summary
Compositions and methods for the treatment of an ocular disease or disorder are disclosed.